Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
REGN - Regeneron Pharmaceuticals, Inc.
Market Cap 87.20B P/E 20.55 EPS this Y -7.80% Ern Qtrly Grth -46.30%
Income 4.34B Forward P/E 17.69 EPS next Y 8.80% 50D Avg Chg 6.00%
Sales 12.17B PEG -1.10 EPS past 5Y 26.71% 200D Avg Chg 15.00%
Dividend N/A Price/Book 3.77 EPS next 5Y -16.60% 52W High Chg -2.00%
Recommedations 2.30 Quick Ratio 4.16 Shares Outstanding 107.51M 52W Low Chg 48.00%
Insider Own 2.56% ROA 11.42% Shares Float 102.10M Beta 0.21
Inst Own 89.77% ROE 20.94% Shares Shorted/Prior 1.20M/1.46M Price 797.63
Gross Margin 57.67% Profit Margin 35.64% Avg. Volume 606,766 Target Price 841.13
Oper. Margin 41.03% Earnings Date May 2 Volume 1,326,244 Change 6.17%
Healthcare | Biotechnology | United States
About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Regeneron Pharmaceuticals, Inc. News
11:08 AM Why Shares of Regeneron Are Rising Thursday
09:25 AM Regeneron Breaks Out On Home Run In 'Smoker's Lung' As Sanofi Soars
09:00 AM Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?
08:20 AM Why Regeneron Pharmaceuticals And Sanofi Shares Are Trading Higher Today
07:14 AM Sanofi, Regeneron’s Drug Succeeds in High-Stakes Lung Trial
03:12 AM Sanofi rises as analysts eye results from smoker's lung drug trial
01:45 AM UPDATE 3-Sanofi, Regeneron unveil 'blow-out' smoker's lung drug data
01:00 AM Sanofi and Regeneron's Dupixent meets endpoints in clinical trial
01:00 AM Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial
03/22/23 Regeneron (REGN) Gets Label Extension for Cholesterol Drug
03/22/23 UPDATE 3-US FDA expands use of Regeneron's cholesterol drug in young children
03/22/23 FDA Approves First-in-class Evkeeza® (evinacumab-dgnb) for Young Children with Ultra-rare Form of High Cholesterol
03/21/23 Regeneron (REGN) Gains But Lags Market: What You Should Know
03/21/23 Sanofi's (SNY) Dupixent Gets EU Nod for Eczema in Young Kids
03/21/23 Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis
03/18/23 Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis
03/18/23 Investing in Regeneron Pharmaceuticals (NASDAQ:REGN) five years ago would have delivered you a 133% gain
03/17/23 Regeneron (REGN) Gains 9.3% in a Year: Will the Uptrend Last?
03/17/23 Medicare Negotiation Undercuts Biotech Stocks Regeneron, Halozyme
03/16/23 Dow Jones Hits Session Highs; Tesla Faces New Lawsuit From Customers, Agrees To Open 7500 Charging Stations
REGN Chatroom

User Image SpartansTrading Posted - 6 minutes ago

Pre-market Action Plan Today: $TSLA Long idea 3pts $REGN flat $ASML Long idea 15pts+ $NVDA Long idea 3pts+ https://t.co/OW5PQYeoFo

User Image SparkNewswire Posted - 10 minutes ago

Pre-market Action Plan Today: $TSLA Long idea 3pts $REGN flat $ASML Long idea 15pts+ $NVDA Long idea 3pts+ https://t.co/MqYGFyjLxU https:

User Image MariaC82 Posted - 47 minutes ago

Upgrades, Downgrades, Initiations & More: $MRO $REGN $PXD $ISRG $FSLR

User Image macroaxis Posted - 1 hour ago

$CCL - Compare Carnival with Regeneron Pharmaceuticals ( $REGN ). Earnings call this week https://www.macroaxis.com/competition/CCL/REGN/Carnival-vs-Regeneron #portfolio_prospective #better_portfolio #diversify

User Image STCKPRO Posted - 1 hour ago

$REGN NEW ARTICLE : REGN Stock Alert: Regeneron Pharmaceuticals Gains on Dupixent Drug Data https://www.stck.pro/news/REGN/45277658

User Image ChartMill Posted - 1 hour ago

An Altman-Z score of 10.14 indicates that $REGN is not in any danger for bankruptcy at the moment. https://www.chartmill.com/stock/quote/REGN/fundamental-analysis?key=f5b4972b-17e1-4ced-b304-cc05791dfc2f&utm_source=stocktwits&utm_medium=FA&utm_content=REGN&utm_campaign=social_tracking

User Image stocktargetadvisors Posted - 1 hour ago

$REGN latest rating from EF Hutton and Company on 2023-03-23, setting target price at: USD 862.00 with a rating of Buy. The average analyst target price isUSD 849.03. StockTargetAdvisor's own view is Slightly Bullish . Details: https://www.stocktargetadvisor.com/stock/USA/NSD/REGN

User Image MarketBeat Posted - 2 hours ago

Regeneron Pharmaceuticals upgraded by Raymond James to market perform. www.marketbeat.com/stocks/NASDAQ/REGN/price-target/ $REGN

User Image tradethehalt Posted - 2 hours ago

$SNY $REGN Key News Update Dupixent shows potential as first biologic to treat COPD with significant reduction in exacerbations according to Regeneron and Sanofi's pivotal trial https://www.marketwatch.com/story/regeneron-sanofi-say-dupixent-works-in-copd-87a00cbc

User Image InvestorPlace Posted - 2 hours ago

Here's the clinical trial data sending $REGN higher today! https://investorplace.com/2023/03/regn-stock-alert-regeneron-pharmaceuticals-gains-on-dupixent-drug-data/

User Image ChartMill Posted - 2 hours ago

$NFLX, $FRC and $REGN are the top gainers in the S&P500 for the day. https://www.chartmill.com/stock/stock-screener?v=3&f=ind_22&s=pt&utm_source=stocktwits&utm_medium=screener&utm_content=Stock_Screener:_top_S&P500_gainers&utm_campaign=social_tracking

User Image quantcha Posted - 2 hours ago

52-Week High Alert: Trading today's movement in REGENERON PHARMACEUTICALS $REGN https://ideas.quantcha.com/?p=3136

User Image Quantisnow Posted - 2 hours ago

$REGN 📋 Regeneron Pharma upgraded by Raymond James https://quantisnow.com/i/4240225?utm_source=stocktwits 45 seconds delayed.

User Image quantcha Posted - 2 hours ago

Big Gainer Alert: Trading today's 7.1% move in REGENERON PHARMACEUTICALS $REGN https://ideas.quantcha.com/?p=3124

User Image net0trader Posted - 3 hours ago

$REGN Massive range breakout to new highs... @MaverikIT @Im_not_Mr_Lebowski

User Image stockilluminati Posted - 3 hours ago

$REGN https://www.stockilluminati.com/regn/news.php - Thinking about trading options or stock in Regeneron Pharmaceuticals, NetEase, Netflix, Advanced Micro Devices, or Novo Nordisk?

User Image STCKPRO Posted - 3 hours ago

$REGN NEW ARTICLE : Regeneron, Sanofi Soar On Blow-Out Results In 'Smoker's Lung' https://www.stck.pro/news/REGN/45275437

User Image thetechtrader Posted - 3 hours ago

$REGN targets are 820, 830 & maybe 840. Support 800. $SNY targets are 53 & 54.50+ Support 51.25-.35. @HarryBoxer @TheTechTrader https://thetechtrader.com/ #swingtrading #technicaltrading #stockmarketrecap #stockmarket #swingtrader

User Image MOMOPro Posted - 3 hours ago

$REGN Gap

User Image sleekoptions_twits Posted - 3 hours ago

Peak profit for the last 6 expired option alerts for $REGN -94.30| -75.68| -99.57| 82.67| 244.44| 197.56|

User Image net0trader Posted - 3 hours ago

@MaverikIT @_RangeTrader_ @Im_not_Mr_Lebowski $REGN flying…

User Image Jack90 Posted - 4 hours ago

$REGN $SOFI

User Image AlertsAndNews Posted - 4 hours ago

$SNY $REGN Sanofi, Regeneron unveil 'blow-out' smoker's lung drug data https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-regenerons-dupixent-meets-endpoints-clinical-trial-2023-03-23/

User Image SweepCast Posted - 4 hours ago

SweepCast ⚡ Unusual Options Detected: $REGN with Unusual Options Activity Alerted on $725 PUT Expiring: 05-19-2023 worth 43K🐻 |🥇 Start Using SweepCast! @SweepCast 🥇 |

User Image BPPharmaguy Posted - 4 hours ago

$REGN BOOM! Deep OTM calls now deep ITM. Great job, REGN

User Image Street_Insider Posted - 5 hours ago

$SNY $REGN Sanofi rises as analysts eye results from smoker's lung drug trial https://www.streetinsider.com/Analyst+Comments/Sanofi+rises+as+analysts+eye+results+from+smokers+lung+drug+trial/21408777.html

User Image briefingcom Posted - 5 hours ago

$REGN (+8%) and $SNY (+6.6%) report Dupixent demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial.

User Image OpenOutcrier Posted - 5 hours ago

$SNY (+6.6% pre) $REGN (+8.5% pre) Sanofi (SNY) and Regeneron (REGN) Report Dupixent Met Endpoints in Phase 3 Trial for COPD - SI http://ooc.bz/l/124180

User Image risenhoover Posted - 8 hours ago

$REGN REGN / Regeneron Pharmaceuticals Inc Price Target Updated https://fintel.io/sfo/us/regn?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

User Image STCKPRO Posted - 9 hours ago

$REGN NEW ARTICLE : Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial https://www.stck.pro/news/REGN/45258626

Analyst Ratings
BMO Capital Outperform Mar 14, 23
RBC Capital Sector Perform Mar 9, 23
EF Hutton Buy Feb 24, 23
Wells Fargo Overweight Feb 21, 23
Wells Fargo Overweight Feb 17, 23
EF Hutton Buy Feb 8, 23
RBC Capital Sector Perform Feb 6, 23
Baird Neutral Feb 6, 23
Morgan Stanley Overweight Feb 6, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
VAGELOS P ROY Director Director Feb 22 Option 270.43 42,500 11,493,275 366,583 02/24/23
Landry Robert E EVP Finance CFO EVP Finance CFO Oct 31 Option 381.92 2,000 763,840 30,744 11/02/22
Landry Robert E EVP Finance CFO EVP Finance CFO Oct 31 Sell 757.9 482 365,308 28,744 11/02/22
McCourt Marion EVP Commercial EVP Commercial Nov 01 Option 372.46 1,100 409,706 20,744 11/02/22
McCourt Marion EVP Commercial EVP Commercial Nov 01 Sell 750 1,100 825,000 19,644 11/02/22
Tessier-Lavigne Marc Director Director Sep 29 Option 413.33 10,838 4,479,671 5,881 10/03/22
Tessier-Lavigne Marc Director Director Sep 29 Sell 696.44 10,838 7,548,017 2,269 10/03/22
Bassler Bonnie L Director Director Sep 08 Option 386.84 3,167 1,225,122 1,691 09/12/22
Bassler Bonnie L Director Director Sep 08 Sell 711 3,167 2,251,737 1,082 09/12/22
LAROSA JOSEPH J EVP General Counsel.. EVP General Counsel and Secret Sep 09 Option 270.43 30,000 8,112,900 41,580 09/12/22
RYAN ARTHUR F Director Director Aug 04 Sell 621.48 10,453 6,496,330 19,682 08/08/22
RYAN ARTHUR F Director Director Aug 04 Option 412.58 10,453 4,312,699 21,092 08/08/22
STAHL NEIL EVP Research and Dev.. EVP Research and Development Aug 04 Option 270.43 95,000 25,690,850 147,795 08/08/22
STAHL NEIL EVP Research and Dev.. EVP Research and Development Aug 04 Sell 613.95 23,782 14,600,959 52,795 08/08/22
RYAN ARTHUR F Director Director May 02 Sell 650.58 100 65,058 22,182 05/03/22
McCourt Marion EVP Commercial EVP Commercial May 02 Option 342.93 1,100 377,223 20,744 05/03/22
McCourt Marion EVP Commercial EVP Commercial May 02 Sell 656.97 1,100 722,667 19,644 05/03/22
Landry Robert E EVP Finance CFO EVP Finance CFO Apr 07 Option 393.75 9,500 3,740,625 32,158 04/11/22
Landry Robert E EVP Finance CFO EVP Finance CFO Apr 07 Sell 735.54 2,187 1,608,626 28,744 04/11/22
LAROSA JOSEPH J EVP General Counsel.. EVP General Counsel and Secret Apr 07 Sell 721.1 5,114 3,687,705 16,900 04/11/22
Fenimore Christopher R. SVP Controller SVP Controller Apr 08 Option 413.05 7,450 3,077,222 30,066 04/11/22
Bassler Bonnie L Director Director Apr 07 Option 380.95 1,240 472,378 2,322 04/11/22
Bassler Bonnie L Director Director Apr 07 Sell 725 1,240 899,000 1,082 04/11/22
Landry Robert E EVP Finance CFO EVP Finance CFO Mar 28 Sell 688.04 2,683 1,846,011 28,744 03/30/22
Landry Robert E EVP Finance CFO EVP Finance CFO Mar 28 Option 462.06 14,500 6,699,870 34,212 03/30/22
Van Plew Daniel P EVP & General Mgr, I.. EVP & General Mgr, Industrial Feb 22 Option 399.66 40,000 15,986,400 70,578 02/24/22
Van Plew Daniel P EVP & General Mgr, I.. EVP & General Mgr, Industrial Feb 22 Sell 612.92 6,781 4,156,211 30,578 02/24/22
BROWN MICHAEL S Director Director Feb 23 Sell 608.68 500 304,340 7,162 02/24/22
MURPHY ANDREW J EVP Research EVP Research Feb 14 Option 179.13 10,000 1,791,300 68,470 02/16/22
MURPHY ANDREW J EVP Research EVP Research Feb 14 Sell 629.34 3,540 2,227,864 58,470 02/16/22
MURPHY ANDREW J EVP Research EVP Research Dec 08 Option 52.03 16,500 858,495 75,667 12/10/21
MURPHY ANDREW J EVP Research EVP Research Dec 08 Sell 664.97 7,122 4,735,916 59,167 12/10/21
Tessier-Lavigne Marc Director Director Dec 09 Option 371.4 3,784 1,405,378 5,862 12/10/21
Tessier-Lavigne Marc Director Director Dec 09 Sell 665 3,784 2,516,360 2,078 12/10/21
Landry Robert E EVP Finance CFO EVP Finance CFO Dec 08 Option 399.66 4,250 1,698,555 34,207 12/10/21
Landry Robert E EVP Finance CFO EVP Finance CFO Dec 08 Sell 664.66 781 519,099 29,957 12/10/21
LAROSA JOSEPH J EVP General Counsel.. EVP General Counsel and Secret Dec 08 Option 179.13 30,000 5,373,900 46,520 12/10/21
SCHLEIFER LEONARD S President & CEO President & CEO Nov 19 Option 224.78 520,313 116,955,956 651,568 11/19/21
BROWN MICHAEL S Director Director Jan 27 Option 380.95 2,480 944,756 3,371 01/27/21
BROWN MICHAEL S Director Director Jan 27 Sell 554.32 2,480 1,374,714 891 01/27/21
YANCOPOULOS GEORGE President and Chief.. President and Chief Scientific Dec 31 Option 52.03 398,079 20,712,050 908,303 12/31/20
MURPHY ANDREW J EVP Research EVP Research Nov 18 Option 30.63 13,736 420,734 60,872 11/18/20
MURPHY ANDREW J EVP Research EVP Research Nov 18 Sell 545.61 6,628 3,616,303 47,136 11/18/20
RYAN ARTHUR F Director Director Nov 03 Sell 548.92 100 54,892 23,743 11/03/20
BROWN MICHAEL S Director Director Sep 23 Option 378.82 5,090 1,928,194 5,733 09/23/20
BROWN MICHAEL S Director Director Sep 23 Sell 552.36 6,090 3,363,872 9,349 09/23/20
GOLDSTEIN JOSEPH L Director Director Sep 23 Option 376.35 16,574 6,237,625 22,217 09/23/20
GOLDSTEIN JOSEPH L Director Director Sep 23 Sell 549.84 16,574 9,113,048 5,643 09/23/20